- Home
- GENC vs GALT Comparison
GENC vs GALT Comparison
Compare GENC & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENC
- GALT
- Stock Information
- Founded
- GENC 1894
- GALT 2000
- Country
- GENC United States
- GALT United States
- Employees
- GENC N/A
- GALT N/A
- Industry
- GENC Construction/Ag Equipment/Trucks
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- GENC Industrials
- GALT Health Care
- Exchange
- GENC Nasdaq
- GALT Nasdaq
- Market Cap
- GENC 206.8M
- GALT 232.3M
- IPO Year
- GENC N/A
- GALT N/A
- Fundamental
- Price
- GENC $16.46
- GALT $4.04
- Analyst Decision
- GENC
- GALT Strong Buy
- Analyst Count
- GENC 0
- GALT 3
- Target Price
- GENC N/A
- GALT $6.00
- AVG Volume (30 Days)
- GENC 68.0K
- GALT 241.8K
- Earning Date
- GENC 08-08-2025
- GALT 08-14-2025
- Dividend Yield
- GENC N/A
- GALT N/A
- EPS Growth
- GENC N/A
- GALT N/A
- EPS
- GENC 1.03
- GALT N/A
- Revenue
- GENC $117,527,000.00
- GALT N/A
- Revenue This Year
- GENC N/A
- GALT N/A
- Revenue Next Year
- GENC N/A
- GALT N/A
- P/E Ratio
- GENC $15.60
- GALT N/A
- Revenue Growth
- GENC 3.90
- GALT N/A
- 52 Week Low
- GENC $10.80
- GALT $0.73
- 52 Week High
- GENC $22.82
- GALT $4.41
- Technical
- Relative Strength Index (RSI)
- GENC 64.27
- GALT 61.42
- Support Level
- GENC $14.31
- GALT $3.93
- Resistance Level
- GENC $15.90
- GALT $4.19
- Average True Range (ATR)
- GENC 0.68
- GALT 0.27
- MACD
- GENC 0.11
- GALT -0.03
- Stochastic Oscillator
- GENC 102.44
- GALT 72.00
About GENC Gencor Industries Inc.
Gencor Industries Inc and its subsidiaries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company has one reporting segment, equipment for the highway construction industry. The firm's principal products include asphalt plants, combustion systems, hot mix asphalt plants, fluid heat transfer systems, and asphalt pavers.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.